Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dermata Therapeutics (DRMA)
NASDAQ:DRMA
Dermata Therapeutics (DRMA) Stock Price & Analysis
63 Followers
DRMA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.80 - $24.59
Previous Close$1.81
Volume51.78K
Average Volume (3M)63.02K
Market Cap
$1.26M
Enterprise Value$1.26M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Sep 23, 2024EPS Estimate
-$3.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-32.72
Shares Outstanding444,056
10 Day Avg. Volume71,950
30 Day Avg. Volume63,015
Standard Deviation0.22
R-Squared0.04
Alpha-0.14
Financial Highlights & Ratios
Price to Book (P/B)0.18
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.18
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.14
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
Dermata Therapeutics News
PremiumCompany Announcements
Dermata Therapeutics Unveils Key Financial Results and EfficienciesPremiumCompany Announcements
Dermata Therapeutics Enhances Equity Plan and Approves Stock Split
PremiumCompany Announcements
Dermata Therapeutics: Unveiling Recent Financial PerformanceBulls Say, Bears Say
Bulls Say
Analyst RatingsAnalyst maintains a Buy rating, seeing value in DRMA's innovative technology and potential in the acne treatment market.
Clinical TrialsDRMA is making progress in advancing DMT310 for acne treatment through the regulatory pathway.
Financial PerformanceDRMA reported operating expenses below estimates and a narrower GAAP loss per share, reflecting effective cost management.
Bears Say
FundingDRMA will require additional funding by 3Q24 given its current cash burn rate.
Price TargetDue to dilution from warrant exercises and anticipation of a capital raise, the price target has been lowered to $10.00 from a split-adjusted $22.50.
Revenue EstimatesLowered revenue estimates and price target to $1.50, indicating tempered expectations for near-term financial performance.
---
DRMA FAQ
What was Dermata Therapeutics’s price range in the past 12 months?
Dermata Therapeutics lowest stock price was $1.80 and its highest was $24.59 in the past 12 months.
What is Dermata Therapeutics’s market cap?
Currently, no data Available
When is Dermata Therapeutics’s upcoming earnings report date?
Dermata Therapeutics’s upcoming earnings report date is Sep 23, 2024 which is in 66 days.
How were Dermata Therapeutics’s earnings last quarter?
Dermata Therapeutics released its earnings results on May 15, 2024. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$5.4 by $4.93.
Is Dermata Therapeutics overvalued?
According to Wall Street analysts Dermata Therapeutics’s price is currently Overvalued.
Does Dermata Therapeutics pay dividends?
Dermata Therapeutics does not currently pay dividends.
What is Dermata Therapeutics’s EPS estimate?
Dermata Therapeutics’s EPS estimate is -$3.79.
How many shares outstanding does Dermata Therapeutics have?
Dermata Therapeutics has 693,175 shares outstanding.
What happened to Dermata Therapeutics’s price movement after its last earnings report?
Dermata Therapeutics reported an EPS of -$0.47 in its last earnings report, beating expectations of -$5.4. Following the earnings report the stock price went up 5.051%.
Which hedge fund is a major shareholder of Dermata Therapeutics?
Currently, no hedge funds are holding shares in DRMA
---
Dermata Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-91.71%
12-Months-Change
Fundamentals
Return on Equity
-146.08%
Trailing 12-Months
Asset Growth
-44.27%
Trailing 12-Months
Company Description
Dermata Therapeutics
Dermata Therapeutics Inc is a clinical-stage biotechnology company. It is focused on the treatment of multiple medical and aesthetic skin conditions and diseases with high unmet needs.
---
DRMA Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering DRMA
1 Year
1 Year Success Rate
0/14 ratings generated profit
1 Year Average Return
-82.06%
reiterated a buy rating 2 months ago
Copying Anthony Vendetti's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -82.06% per trade.
---